For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Revelation Biosciences Inc (NASDAQ: REVB) closed the day trading at $0.82 up 9.33% from the previous closing price of $0.75. In other words, the price has increased by $9.33 from its previous closing price. On the day, 0.41 million shares were traded. REVB stock price reached its highest trading level at $0.8295 during the session, while it also had its lowest trading level at $0.702.
Ratios:
For a better understanding of REVB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.61 and its Current Ratio is at 3.61. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REVB now has a Market Capitalization of 3775116 and an Enterprise Value of -2981764.
Stock Price History:
The Beta on a monthly basis for REVB is -0.08, which has changed by -0.9708972 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, REVB has reached a high of $56.00, while it has fallen to a 52-week low of $0.71. The 50-Day Moving Average of the stock is -57.66%, while the 200-Day Moving Average is calculated to be -87.40%.
Shares Statistics:
Over the past 3-months, REVB traded about 1.05M shares per day on average, while over the past 10 days, REVB traded about 494130 shares per day. A total of 2.03M shares are outstanding, with a floating share count of 2.03M. Insiders hold about 0.03% of the company’s shares, while institutions hold 1.89% stake in the company. Shares short for REVB as of 1749772800 were 152953 with a Short Ratio of 0.15, compared to 1747267200 on 41764. Therefore, it implies a Short% of Shares Outstanding of 152953 and a Short% of Float of 3.32.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Revelation Biosciences Inc (REVB) reflects the combined expertise of 2.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.24, with high estimates of -$0.48 and low estimates of -$1.99.
Analysts are recommending an EPS of between -$2.78 and -$8.09 for the fiscal current year, implying an average EPS of -$5.43. EPS for the following year is -$1.94, with 1.0 analysts recommending between -$1.94 and -$1.94.
